Besides sunitinib and regorafenib being accepted as the second- and third-line therapies for advanced GIST, cabozatinib and the multiple RTKi, including VEGFR2, can also be considered as a further treatment line for GIST. The gene discussed is KDR; the disease is gastrointestinal stromal tumor.